Study of sapablursen for phlebotomy-dependent polycythemia vera
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests an investigational drug called sapablursen for people with polycythemia vera who still need frequent phlebotomies. The goal is to see if the drug can reduce the need for blood removal and help control the disease safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have polycythemia vera diagnosed using the latest 2022 criteria.
- You need regular blood removal (phlebotomy) to keep your red blood cells in check.
- Your hematocrit level is below 45% when the study starts.
- If you take medication to lower blood counts, your dose has been stable.
- You have not had a blood clot (like a stroke or heart attack) in the past month.
- You have never taken sapablursen or similar drugs (TMPRSS6 inhibitors) before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called AG-236 in people with polycythemia vera (PV), a condition where the body makes too many red blood cells. The trial aims to see if AG-236 can reduce the need for phlebotomies (removing blood to lower red blood cell count) and help control the disease.
This study tests an injection called BEBT-507 for people with polycythemia vera (a blood condition that makes too many red blood cells). It's for those who haven't responded well to or can't tolerate standard treatments like hydroxyurea or interferon. The goal is to see if this new drug can help control the disease.
This trial tests a new drug called rusfertide for adults with polycythemia vera whose red blood cell levels are not well controlled. The drug is given as an injection and may help reduce the need for phlebotomy (blood removal) and manage symptoms.
This trial tests a new drug called 9MW3011 for people with polycythemia vera (PV) who haven't done well on or can't take standard treatments like hydroxyurea or interferon. The goal is to see if the drug is safe and how it works in your body.
This study tests a new medicine called rusfertide for polycythemia vera (PV)—a blood condition where your body makes too many red blood cells. The trial aims to see if rusfertide can help reduce the need for blood removal procedures (phlebotomy) that PV patients currently need to manage their condition.
This Phase 2 trial tests a combination of pegylated interferon and ruxolitinib in adults with polycythemia vera who can’t tolerate hydroxyurea or don’t respond well to it. If you qualify, it may help control blood counts and disease symptoms when standard treatment hasn’t worked.
Hear when a new Polycythemia Vera trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.